English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Using a unique resource of samples from a controlled human malaria infection (CHMI) study, we identified a novel population of CD4 +  T cells whose frequency in the peripheral blood was inversely correlated with parasite burden following  P .  falciparum  infection. These CD4 +  T cells expressed the multifunctional ectoenzyme CD38 and had unique features that distinguished them from other CD4 +  T cells. Specifically, their phenotype was associated with proliferation, activation and cytotoxic potential as well as significantly impaired production of IFN-γ and other cytokines and reduced basal levels of activated STAT1. A CD38 +  CD4 +  T cell population with similar features was identified in healthy uninfected individuals, at lower frequency. CD38 +  CD4 +  T cells could be generated  in vitro  from CD38 -  CD4 +  T cells after antigenic or mitogenic stimulation. This is the first report of a population of CD38 +  CD4 +  T cells with a cytotoxic phenotype and markedly impaired IFN-γ capacity in humans. The expansion of this CD38 +  CD4 +  T population following infection and its significant association with reduced blood-stage parasite burden is consistent with an important functional role for these cells in protective immunity to malaria in humans. Their ubiquitous presence in humans suggests that they may have a broad role in host-pathogen defense.   Trial Registration  ClinicalTrials.gov clinical trial numbers  ACTRN12612000814875 ,  ACTRN12613000565741  and  ACTRN12613001040752

Reduced Plasmodium Parasite Burden Associates with CD38+ CD4+ T Cells Displaying Cytolytic Potential and Impaired IFN-γ Production